Objectives To identify the use and adverse drug reactions associated with azithromycin in neonates. Setting Databases MEDLINE (1948–August 2015), EMBASE (1980–August 2015) and Pubmed (August 2015) were searched for studies on azithromycin in neonates. Participants All studies involving neonates (<28 days old) who have received at least a single dose of azithromycin for which safety was evaluated. Primary and secondary outcome measures The primary outcome was adverse event (AE) associated with use of azithromycin. Use of azithromycin in neonates was the secondary outcome. Results A total of 11 articles involving 473 neonates were identified. 371 AEs were reported. Adverse events were mainly respiratory (358/1000 neonate), neurolo...
Mass azithromycin distribution reduces all-cause childhood mortality in some high-mortality settings...
A survey was set up to gauge the opinions of neonatologists on the role of Ureaplasma in bronchopulm...
Background: Preterm birth, especially at less than 30 weeks’ gestation, is significantly associated ...
Objectives To identify the use and adverse drug reactions associated with azithromycin in neonates. ...
IntroductionBiannual mass azithromycin distribution to children aged 1-59 months has been shown to r...
Objective Since preventive therapies for bronchopulmonary dysplasia (BPD) are limited we treated pre...
Adverse events following azithromycin treatment among infants aged 1–5 months in communities randomi...
BACKGROUND:Mass azithromycin distribution reduces under-5 child mortality. Trachoma control programs...
BackgroundMass azithromycin distribution reduces under-5 child mortality. Trachoma control programs ...
BACKGROUND: Azithromycin reduces the severity of illness in patients with inflammatory lung disease ...
Background: Currently there are trials in Africa and Asia investigating whether prophylactic azithro...
Background: The role of Ureaplasma Urealyticum (UU) colonisation of the lungs remains controversial ...
Introduction: Azithromycin is widely used in children not only in the treatment of individual childr...
Mass azithromycin distribution reduces all-cause childhood mortality in some high-mortality settings...
A survey was set up to gauge the opinions of neonatologists on the role of Ureaplasma in bronchopulm...
Background: Preterm birth, especially at less than 30 weeks’ gestation, is significantly associated ...
Objectives To identify the use and adverse drug reactions associated with azithromycin in neonates. ...
IntroductionBiannual mass azithromycin distribution to children aged 1-59 months has been shown to r...
Objective Since preventive therapies for bronchopulmonary dysplasia (BPD) are limited we treated pre...
Adverse events following azithromycin treatment among infants aged 1–5 months in communities randomi...
BACKGROUND:Mass azithromycin distribution reduces under-5 child mortality. Trachoma control programs...
BackgroundMass azithromycin distribution reduces under-5 child mortality. Trachoma control programs ...
BACKGROUND: Azithromycin reduces the severity of illness in patients with inflammatory lung disease ...
Background: Currently there are trials in Africa and Asia investigating whether prophylactic azithro...
Background: The role of Ureaplasma Urealyticum (UU) colonisation of the lungs remains controversial ...
Introduction: Azithromycin is widely used in children not only in the treatment of individual childr...
Mass azithromycin distribution reduces all-cause childhood mortality in some high-mortality settings...
A survey was set up to gauge the opinions of neonatologists on the role of Ureaplasma in bronchopulm...
Background: Preterm birth, especially at less than 30 weeks’ gestation, is significantly associated ...